D
Achilles Therapeutics plc
ACHL
$1.48
$0.010.68%
D
Sell
7/29/2024Upgraded
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 7/29/2024 due to an increase in the volatility index.
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 7/29/2024 due to an increase in the volatility index.
E
Sell
7/12/2024Downgrade
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 7/12/2024 due to a noticeable decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.02 to 0.03.
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 7/12/2024 due to a noticeable decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.02 to 0.03.
D
Sell
5/29/2024Upgraded
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 5/29/2024 due to an increase in the volatility index and total return index.
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 5/29/2024 due to an increase in the volatility index and total return index.
E
Sell
5/14/2024Downgrade
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 5/14/2024 due to a decline in the volatility index, growth index and valuation index.
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 5/14/2024 due to a decline in the volatility index, growth index and valuation index.
D
Sell
4/29/2024Upgraded
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 4/29/2024 due to an increase in the volatility index and valuation index.
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 4/29/2024 due to an increase in the volatility index and valuation index.
E
Sell
4/12/2024Downgrade
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 4/12/2024 due to a decline in the growth index, volatility index and solvency index. Operating cash flow declined 1,516.07% from $1M to -$14.19M, earnings per share declined from -$0.4164 to -$0.4636, and EBIT declined 1.67% from -$19.1M to -$19.41M.
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 4/12/2024 due to a decline in the growth index, volatility index and solvency index. Operating cash flow declined 1,516.07% from $1M to -$14.19M, earnings per share declined from -$0.4164 to -$0.4636, and EBIT declined 1.67% from -$19.1M to -$19.41M.
D
Sell
4/1/2024Upgraded
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 4/1/2024 due to a noticeable increase in the total return index and volatility index.
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 4/1/2024 due to a noticeable increase in the total return index and volatility index.
E
Sell
3/14/2024Downgrade
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 3/14/2024 due to a decline in the volatility index.
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 3/14/2024 due to a decline in the volatility index.
D
Sell
2/27/2024Upgraded
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 2/27/2024 due to an increase in the volatility index, total return index and solvency index.
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 2/27/2024 due to an increase in the volatility index, total return index and solvency index.
E
Sell
3/14/2023Downgrade
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 3/14/2023 due to a decline in the growth index and total return index. Earnings per share declined from -$0.3173 to -$0.6087.
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 3/14/2023 due to a decline in the growth index and total return index. Earnings per share declined from -$0.3173 to -$0.6087.
D
Sell
2/23/2023Upgraded
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 02/23/2023.
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
12/2/2022Downgrade
Achilles Therapeutics plc (ACHL) was downgraded to D- from D on 12/2/2022 due to a decline in the volatility index and total return index.
Achilles Therapeutics plc (ACHL) was downgraded to D- from D on 12/2/2022 due to a decline in the volatility index and total return index.
D
Sell
11/15/2022Upgraded
Achilles Therapeutics plc (ACHL) was upgraded to D from D- on 11/15/2022 due to a noticeable increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.4462 to -$0.3173, and EBIT increased 15.47% from -$18.97M to -$16.03M.
Achilles Therapeutics plc (ACHL) was upgraded to D from D- on 11/15/2022 due to a noticeable increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.4462 to -$0.3173, and EBIT increased 15.47% from -$18.97M to -$16.03M.
D
Sell
8/18/2022Upgraded
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 8/18/2022 due to an increase in the volatility index and total return index.
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 8/18/2022 due to an increase in the volatility index and total return index.
E
Sell
8/2/2022Downgrade
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 8/2/2022 due to a decline in the volatility index.
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 8/2/2022 due to a decline in the volatility index.
D
Sell
7/14/2022Upgraded
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 7/14/2022 due to an increase in the volatility index and total return index.
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 7/14/2022 due to an increase in the volatility index and total return index.
E
Sell
6/27/2022Downgrade
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 6/27/2022 due to a decline in the volatility index and valuation index.
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 6/27/2022 due to a decline in the volatility index and valuation index.
D
Sell
5/5/2022Upgraded
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 05/05/2022.
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 05/05/2022.
E
Sell
4/20/2022Downgrade
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 4/20/2022 due to a decline in the solvency index and total return index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 16.72 to 14.52.
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 4/20/2022 due to a decline in the solvency index and total return index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 16.72 to 14.52.
D
Sell
2/16/2022Upgraded
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 2/16/2022 due to an increase in the volatility index.
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 2/16/2022 due to an increase in the volatility index.
E
Sell
1/28/2022Downgrade
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 1/28/2022 due to a decline in the volatility index and total return index.
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 1/28/2022 due to a decline in the volatility index and total return index.
D
Sell
1/3/2022Upgraded
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 1/3/2022 due to an increase in the volatility index.
Achilles Therapeutics plc (ACHL) was upgraded to D- from E+ on 1/3/2022 due to an increase in the volatility index.
E
Sell
12/16/2021Downgrade
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 12/16/2021 due to a decline in the volatility index and total return index.
Achilles Therapeutics plc (ACHL) was downgraded to E+ from D- on 12/16/2021 due to a decline in the volatility index and total return index.
D
Sell
12/1/2021Upgraded
Achilles Therapeutics plc (ACHL) was upgraded to D- from E on 12/01/2021.
Achilles Therapeutics plc (ACHL) was upgraded to D- from E on 12/01/2021.
E
Sell
9/1/2021Upgraded
Achilles Therapeutics plc (ACHL) was upgraded to E from E- on 9/1/2021 due to an increase in the growth index and solvency index. Earnings per share increased from -$8.3834 to -$0.4528, debt to equity declined from 0.03 to 0.01, and the quick ratio increased from 11.18 to 16.72.
Achilles Therapeutics plc (ACHL) was upgraded to E from E- on 9/1/2021 due to an increase in the growth index and solvency index. Earnings per share increased from -$8.3834 to -$0.4528, debt to equity declined from 0.03 to 0.01, and the quick ratio increased from 11.18 to 16.72.
E
Sell
6/24/2021None
Achilles Therapeutics plc (ACHL) was downgraded to E- from U on 06/24/2021.
Achilles Therapeutics plc (ACHL) was downgraded to E- from U on 06/24/2021.
NASDAQ
03/20/2025 4:00PM Eastern
Quotes delayed
